adjuvant


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

adjuvant

 [aj´ah-vant, ă-joo´vant]
1. assisting or aiding.
2. a substance that aids another, such as an auxiliary remedy.

ad·ju·vant

(ad'jū-vănt),
1. A substance added to a drug product formulation that affects the action of the active ingredient in a predictable way.
2. immunology a vehicle used to enhance antigenicity; for example, a suspension of minerals (alum, aluminum hydroxide, or phosphate) on which antigen is adsorbed; or water-in-oil emulsion in which antigen solution is emulsified in mineral oil (Freund incomplete adjuvant), sometimes with the inclusion of killed mycobacteria (Freund complete adjuvant) to enhance antigenicity further (inhibits degradation of antigen and/or causes influx of macrophages).
3. Additional therapy given to enhance or extend primary therapy's effect, as in chemotherapy's addition to a surgical regimen.
4. A treatment added to a curative treatment to prevent recurrence of clinical cancer from microscopic residual disease.
[L. ad-juvo, pres. p. -juvans, to give aid to]

adjuvant

(ăj′ə-vənt)
n.
1. A treatment that enhances an existing medical regimen, as a pharmacological agent added to a drug to increase or aid its effect.
2. An immunological agent that increases the antigenic response.
adj.
Contributing to or enhancing an existing medical regimen: adjuvant chemotherapy

Adjuvant

Referring to a management strategy used in addition to the primary therapy.
Immunology A substance that enhances or diversifies the immune response; a nonspecific immune enhancer—e.g., Freund’s adjuvant, BCG vaccine—consisting of particulate-rich oily substances which promotes protein aggregation; adjuvant mixed with an antigen acts as a tissue depot, slowly releasing antigen and activating the immune system.
Pharmacology A drug that modulates the actions of other drugs which, when added to a medication, enhances its pharmacologic effect. See Interference.

adjuvant

Immunology Any nonspecific immune enhancer–eg Freund's adjuvant, BCG vaccine, consisting of a particulate-rich oily substances, which promotes protein aggregation; adjuvant mixed with an antigen acts as a tissue depot, slowly releasing antigen and activating the immune system Oncology The addition of chemotherapy to a traditional therapeutic modality to ↓ M&M Pharmacology A substance which, when added to a medication, enhances its pharmacologic effect. See Neoadjutant.

ad·ju·vant

(ad'jū-vănt)
1. A substance added to a drug product formulation that affects the action of the active ingredient in a predictable way.
2. immunology A vehicle used to enhance antigenicity.
3. Additional therapy given to enhance or extend primary therapy's effect, such as in chemotherapy in addition to a surgical regimen.
4. A treatment added to a curative treatment to prevent recurrence of clinical cancer from microscopic residual disease.
[L. ad-juvo, pres. p. -juvans, to give aid to]

adjuvant

1. Any substance added to a drug to increase its effect.
2. Any substance which, added to an ANTIGEN, non-specifically increases its power to stimulate the production of antibodies (see ANTIBODY).

adjuvant

a substance added to enhance a physical or chemical property, e.g. adjuvants are commonly added to ANTIGENS, improving the IMMUNE RESPONSE in the recipient and thus increasing the production of ANTIBODIES.

ad·ju·vant

(ad'jū-vănt)
1. Substance added to a drug product formulation that affects action of the active ingredient in a predictable way.
2. Additional therapy given to enhance or extend primary therapy's effect, as in chemotherapy's addition to a surgical regimen.
[L. ad-juvo, pres. p. -juvans, to give aid to]
References in periodicals archive ?
Based on the same, the report further dives into the market to provide a precise estimation of the global Adjuvants Market during the ongoing forecast period, where 2019 is the base year and 2025 is the end of the forecast timeline.
The results of the ExteNET trial demonstrated that after two years of follow-up, for patients with hormone receptor positive, HER2-positive early stage breast cancer patients who were treated within one year after the completion of trastuzumab based adjuvant therapy, invasive disease-free survival was 95.3% in the patients treated with neratinib compared with 90.8% in those receiving placebo (hazard ratio = 0.49; 95% CI: (0.30, 0.78); p=0.002).
According to the company, the results of the ExteNET trial demonstrated that after two years of follow-up, for patients with hormone receptor positive, HER2-positive early stage breast cancer patients who were treated within one year after the completion of trastuzumab based adjuvant therapy, invasive disease-free survival (iDFS) was 95.3% in the patients treated with neratinib compared with 90.8% in those receiving placebo.
Pelvic recurrence developed in 11% of patients who did not receive adjuvant radiotherapy (observation or only chemotherapy), whereas none of the patients who underwent radiotherapy had a local recurrence (p=0.310).
In our series, no patients with a RS of less than 18 were recommended adjuvant chemotherapy, consistent with the intent of the Oncotype Dx assay.
'The control arms, which received standard therapy of chemotherapy and Trastuzumab adjuvant therapy alone, still did well and had a close to 91-percent disease-free survival rate.
Clients can select several ways to work with Adjuvant. This includes embedding an Adjuvant employee in the office of the physician, who can retain the services needed.
Guidelines from the American Urological Association and American Society for Radiation Oncology suggest a more proactive and preventive approach, adjuvant radiation therapy, which is given in the months after surgery before any signs of recurrence appear.
The findings bolster data suggesting that adjuvant therapy can stop or delay recurrence in resected high-risk melanoma.
The aim of this study is to obtain a high titer anti-KDN polyclonal antibody response using safer and more efficient adjuvant systems that are alternative to Freund's adjuvants without using any carrier protein against the hapten-structured KDN molecule.
These findings provide insight on treatment plans for patients with these types of tumors possibly eliminating the need for prescribed adjuvant therapy, preserving quality of life and saving money.